Type 2 Diabetes Clinical Trial
— PRE-STARtOfficial title:
Prevention Strategies for Adolescents at Risk of Diabetes - Validation of a Risk Tool for Young People Aged 12 - 14 Years
NCT number | NCT02545140 |
Other study ID # | 173431 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | October 2015 |
Est. completion date | December 2016 |
Verified date | January 2019 |
Source | University Hospitals, Leicester |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The primary aim of PRE-STARt Phase 1 is to pragmatically evaluate and refine a risk assessment tool to identify those children with chronic disease risk factors (including Type 2 Diabetes).
Status | Completed |
Enrollment | 634 |
Est. completion date | December 2016 |
Est. primary completion date | December 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 12 Years to 14 Years |
Eligibility |
Inclusion Criteria: - Young people aged between 12-14 years of age - be willing and able to give assent - have obtained written parent/guardian consent. Exclusion Criteria: - are outside the age range of interest (i.e. aged less than 12 years or greater than 14 years of age) - do not have parental consent or do not give assent - have an existing diagnosis of type 1 or type 2 diabetes |
Country | Name | City | State |
---|---|---|---|
United Kingdom | University Hospitals of Leicester | Leicester |
Lead Sponsor | Collaborator |
---|---|
University Hospitals, Leicester | Alexander Technological Educational Institute, Thessaloniki, Greece, Associacao Protectora dos Diabeticos de Portugal, Athens General Children's Hospital "Pan. & Aglaia Kyriakou", Basque Government Department of Public Health, Diabetes Centre of Paediatrics P&A, Health Department of the Alto/Bajo Deba, Spain, Primary Care Centre Egia, San Sebastian, Spain, Technische Universität Dresden, The Algarve Regional Health Administration, University of Leicester, University of Leipzig |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Risk tool refinement | A draft risk tool to identify those children with a 'higher risk' of developing type 2 diabetes in the future that has been developed systematic review results and a Delphi procedure. Each adolescent will complete a diet and lifestyle questionnaire about their physical activity, sedentary behaviour and dietary habits and the parent/guardian will complete a questionnaire about their family health history and about their child's early years (including gestational period, birth weight, whether they were breast or bottle fed). This draft tool will be evaluated and refined using these data and the data from the assessments mentioned in 1-9. The draft risk tool will then be refined based on data from the 500 adolescents using appropriate statistical methods resulting in an externally validated risk tool that can be used to screen young people aged between 12-14 years for being at risk of developing of type 2 diabetes in the future. | 18 months | |
Primary | Chronic disease risk factor - Body mass index (BMI) | Height and weight will be measured to calculated BMI | 12 months | |
Secondary | Chronic disease risk factor - waist circumference | 12 months | ||
Secondary | Chronic disease risk factor - blood pressure | 12 months | ||
Secondary | Chronic disease risk factor - glycated haemoglobin (HbA1c) | 12 months | ||
Secondary | Chronic disease risk factor - high density lipoprotein cholesterol | 12 months | ||
Secondary | Chronic disease risk factor - glucose | Fasted and/or unfasted | 12 months | |
Secondary | Chronic disease risk factor - low density lipoprotein cholesterol | Calculated | 12 months | |
Secondary | Chronic disease risk factor - triglycerides | 12 months | ||
Secondary | Chronic disease risk factor - total cholesterol | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
Active, not recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |